Heart & Lung: The Journal of Acute and Critical Care
Volume 37, Issue 4 , Pages 275-285 , July 2008

Diagnostic and prognostic impact of brain natriuretic peptide in cardiac and noncardiac diseases

  • Epaminondas Zakynthinos, MD

      Affiliations

    • Critical Care Department, School of Medicine, University Hospital of Thessaly, Thessaly, Greece
    • Corresponding Author InformationCorresponding author: Epaminondas Zakynthinos, MD, Director of ICU, University Hospital of Thessaly, 41110 Larissa, Greece.
    • ,
  • Theodoros Kiropoulos, RN

      Affiliations

    • Department of Respiratory Medicine, School of Medicine, University Hospital of Thessaly, Thessaly, Greece
    • ,
  • Konstantinos Gourgoulianis, MD

      Affiliations

    • Department of Respiratory Medicine, School of Medicine, University Hospital of Thessaly, Thessaly, Greece
    • ,
  • Gerasimos Filippatos, MD

      Affiliations

    • Department of Cardiology, Atticon University Hospital, Athens, Greece.

References 

  1. American Heart Association. Stroke and statistical update 2002. Dallas, TX: American Heart Association; 2002;
  2. Bukata R. B-natriuretic peptide and congestive heart failure. Emerg Med Acute Care Essays 2003;26.
  3. Shamsham F, Mitchell J. Essentials of the diagnosis of heart failure. Fam Physician. 2000;61:1319–1328
  4. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet. 2003;362:316–322
  5. Silver MA, Maisel A, Yancy CW, et al. BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail. 2004;10(5 Suppl 3):S1–S30
  6. Phua J, Lim TK, Hoe Lee KH. B-type natriuretic peptide: issues for the intensivist and pulmonologist. Crit Care Med. 2005;33:2094–2103
  7. Lang CC, Choy AJ, Struthers AD. Atrial and brain natriuretic peptides: a dual natriuretic peptide system potentially involved in circulatory homeostasis. Clin Sci. 1992;83:519–527
  8. White R. The role of brain natriuretic peptide in systolic heart failure. Dimens Crit Care Nurs. 2005;24:171–174
  9. Hama N, Itoh H, Shirakami G, Nakagawa O, et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation. 1995;92:1558–1564
  10. Li N, Wang J. Brain natriuretic peptide and optimal management of heart failure. J Zhejiang Univ Sci B. 2005;6B:877–884
  11. Lee D, Vasan R. Novel markers for heart failure diagnosis and prognosis. Curr Opin Cardiol. 2005;20:201–210
  12. Grantham JA, Borgeson DD, Burnett JC. BNP: pathophysiological and potential therapeutic roles in acute congestive heart failure. Am J Physiol. 1997;272:R1077–R1083
  13. Yamamoto K, Burnett JC, Redfield MM. Effect of endogenous natriuretic peptide system on ventricular and coronary function in failing heart. Am J Physiol. 1997;273:H2406–H2414
  14. Vanderheyden M, Bartunek J, Goethals M. Brain and other natriuretic peptides: molecular aspects. Eur J Heart Fail. 2004;6:261–268
  15. Hunt PJ, Richards AM, Nicholls MG, et al. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf). 1997;47:287–296
  16. Pemberton CJ, Johnson ML, Yandle TG, Espiner EA. Deconvolution analysis of cardiac natriuretic peptides during acute volume overload. Hypertension. 2000;36:355–359
  17. Richards AM, Crozier IG, Holmes SJ, Espiner EA, Yandle TG, Frampton C. Brain natriuretic peptide: natriuretic and endocrine effects in essential hypertension. J Hypertens. 1993;11:163–170
  18. Jensen KT, Carstens J, Pedersen EB. Effect of BNP on renal hemodynamics tubular function and vasoactive hormones in humans. Am J Physiol. 1998;274(1 Pt 2):F63–F72
  19. Brunner-La Rocca HP, Kaye DM, Woods RL, Hastings J, Esler MD. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol. 2001;37:1221–1227
  20. Clarkson PB, Wheeldon NM, MacFadyen RJ, Pringle SD, MacDonald TM. Effects of brain natriuretic peptide on exercise hemodynamics and neurohormones in isolated diastolic heart failure. Circulation. 1996;93:2037–2042
  21. Cao L, Gardner DG. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension. 1995;25:227–234
  22. Fujisaki H, Ito H, Hirata Y, et al. Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. J Clin Invest. 1995;96:1059–1065
  23. van der Zander K, Houben AJ, Kroon AA, de Leeuw PW. Effects of brain natriuretic peptide on forearm vasculature: comparison with atrial natriuretic peptide. Cardiovasc Res. 1999;44:595–600
  24. van der Zander K, Houben AJ, Kroon AA, De Mey JG, Smits PA, de Leeuw PW. Nitric oxide and potassium channels are involved in brain natriuretic peptide induced vasodilatation in man. J Hypertens. 2002;20:493–499
  25. Maisel AS. Nesiritide: a new therapy for the treatment of heart failure. Cardiovasc Toxicol. 2003;3:37–42
  26. Packer MP. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992;20:248–254
  27. Stevenson LW. Tailored therapy to hemodynamic goals for advanced heart failure. Eur J Heart Fail. 1999;1:251–257
  28. Ferguson DW, Berg WJ, Roach PJ, Oren RM, Mark AL. Effects of heart failure on baroreflex control of sympathetic neural activity. Am J Cardiol. 1992;69:523–531
  29. Grassi G, Seravalle G, Cattaneo BM, et al. Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation. 1995;92:3206–3211
  30. Court O, Kumar A, Parrillo JE, et al. Clinical review: myocardial depression in sepsis and septic shock. Crit Care. 2002;6:500–508
  31. Tomaru Ki K, Arai M, Yokoyama T, et al. Transcriptional activation of the BNP gene by lipopolysaccharide is mediated through GATA elements in neonatal rat cardiac myocytes. J Mol Cell Cardiol. 2002;34:649–659
  32. He Q, LaPointe MC. Interleukin-1beta regulation of the human brain natriuretic peptide promoter involves Ras-, Rac-, and p38 kinase-dependent pathways in cardiac myocytes. Hypertension. 1999;33:283–289
  33. He Q, LaPointe MC. Interleukin-1beta regulates the human brain natriuretic peptide promoter via Ca(2_)-dependent protein kinase pathways. Hypertension. 2000;35:292–296
  34. Kuwahara K, Saito Y, Harada M, et al. Involvement of cardiotrophin-1 in cardiac myocyte-nonmyocyte interactions during hypertrophy of rat cardiac myocytes in vitro. Circulation. 1999;100:1116–1124
  35. Heringlake M, Heide C, Bahlmann L, et al. Effects of tilting and volume loading on plasma levels and urinary excretion of relaxin, NT-pro-ANP, and NT-pro-BNP in male volunteers. J Appl Physiol. 2004;97:173–179
  36. Vieillard-Baron A, Schmitt JM, Augarde R, et al. Acute cor pulmonale in acute respiratory distress syndrome submitted to protective ventilation: incidence, clinical implications, and prognosis. Crit Care Med. 2001;29:1551–1555
  37. Maeder M, Fehr TH, Rickli H, Ammann P. Sepsis-associated myocardial dysfunction. diagnostic and prognostic impact of cardiac troponins and natriuretic peptides. Chest. 2006;129:1349–1366
  38. Jefic D, Lee JW, Jefic D, et al. Utility of B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide in evaluation of respiratory failure in critically ill patients. Chest. 2005;128:288–295
  39. Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol. 2004;43:635–641
  40. Maisel A, Krishnaswamy P, Nowak R, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161–167
  41. Morrison L, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol. 2002;39:202–209
  42. McCullough P, Hollander J, Nowak R, et al. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. Acad Emerg Med. 2003;10:198–210
  43. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004;350:647–654
  44. Storrow A. Advances in the diagnosis of CHF: new markers. Mod Adv Emerg Cardiac Care. 2003;38–48
  45. The Criteria Committee of the New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. Boston: Little, Brown; 1979;
  46. Januzzi JL, Camargo CA, Anwaruddin S, et al. The N-terminal pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005;95:48–54
  47. Jaffe AJ, Babuin L, Apple FS. Biomarkers in acute cardiac disease. the present and the future. J Am Coll Cardiol. 2006;48:1–11
  48. Haug C, Metzele A, Kochs M, Hombach V, Grunert A. Plasma brain natriuretic peptide and atrial natriuretic peptide concentrations correlate with left ventricular end-diastolic pressure. Clin Cardiol. 1993;16:553–557
  49. Kazanegra R, Cheng V, Garcia A, et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail. 2001;7:21–29
  50. Maeda K, Tsutamoto T, Wada A, et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J. 1998;35:825–832
  51. Davis M, Espiner E, Richards G, et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet. 1994;343:440–444
  52. Maisel AS, McCord J, Nowak RM, et al. Breathing Not Properly Multinational Study Investigators Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational StudyJ Am Coll Cardiol. 2003;41:2010–2017
  53. Teng YC, Tang XW, Lin QD, Wu YX, Song XL. Relationship between left ventricular diastolic function and plasma brain natriuretic peptide concentration during severe pregnancy induced hypertension syndrome. Chung Hua I Hsueh Tsa Chih. 2003;83:662–665
  54. Lubien E, DeMaria A, Krishnaswamy P, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation. 2002;105:595–601
  55. Sullivan DR, West M, Jeremy R. Utility of brain natriuretic peptide (BNP) measurement in cardiovascular disease. Heart Lung Circ. 2005;14:78–84
  56. Yoshibayashi M, Kamiya T, Saito Y, Matsuo H. Increased plasma levels of brain natriuretic peptide in hypertrophic cardiomyopathy. N Engl J Med. 1993;329:433–434
  57. Takemura G, Takatsu Y, Doyama K, et al. Expression of atrial and brain natriuretic peptides and their genes in hearts of patients with cardiac amyloidosis. J Am Coll Cardiol. 1998;31:754–765
  58. Maisel A, Hollander JE, Guss D, et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT): a multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol. 2004;44:1328–1333
  59. Vasan RS, Benjamin EJ, Larson MG, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA. 2002;288:1252–1259
  60. Redfield MM, Rodeheffer RJ, Jacobsen SJ, et al. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation. 2004;109:3176–3181
  61. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left ventricular systolic dysfunction. Lancet. 1998;351:9–13
  62. Tateishi J, Masutani M, Ohyanagi M, Iwasaki T. Transient increase in plasma brain (B-type) natriuretic peptide after percutaneous transluminal coronary angioplasty. Clin Cardiol. 2000;23:776–780
  63. Kyriakides ZS, Markianos M, Michalis L, Antoniadis A, Nikolaou NI, Kremastinos DT. Brain natriuretic peptide increases acutely and much more prominently than atrial natriuretic peptide during coronary angioplasty. Clin Cardiol. 2000;23:285–288
  64. Kikuta K, Yasue H, Yoshimura M, et al. Increased plasma levels of B-type natriuretic peptide in patients with unstable angina. Am Heart J. 1996;132(1 Pt 1):101–107
  65. Nagaya N, Nishikimi T, Okano Y, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol. 1998;31:202–208
  66. Gan CT, McCann GP, Marcus JT, et al. Nt-proBNP reflects right ventricular structure and function in pulmonary hypertension. Eur Respir J. 2006;28:1190–1194
  67. Kucher N, Goldhaber SZ. Cardiac biomarkers for risk stratification of patients with acute pulmonary embolism. Circulation. 2003;108:2191–2194
  68. Kruger S, Graf J, Merx MW, et al. Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism. Am Heart J. 2004;147:60–65
  69. Kucher N, Printzen G, Goldhaber SZ. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation. 2003;107:2545–2547
  70. Kucher N, Printzen G, Doernhoefer T, et al. Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation. 2003;107:1576–1578
  71. Incalzi RA, Fuso L, Serra M, et al. Exacerbated chronic obstructive pulmonary disease: a frequently unrecognized condition. J Intern Med. 2002;252:48–55
  72. Gan SC, Beaver SK, Houck PM, et al. Treatment of acute myocardial infarction and 30-day mortality among women and men. N Engl J Med. 2000;343:8–15
  73. Cabanes L, Richaud-Thiriez B, Fulla Y, et al. Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea. Chest. 2001;120:2047–2050
  74. Kita H, Ohi M, Chin K, et al. The nocturnal secretion of cardiac natriuretic peptides during obstructive sleep apnoea and its response to therapy with nasal continuous positive airway pressure. J Sleep Res. 1998;7:199–207
  75. Kaditis A, Alexopoulos E, Hatzi F, et al. Overnight change in brain natriuretic peptide levels in children with sleep-disordered breathing. Chest. 2006;130:1377–1384
  76. Brookes CI, Kemp MW, Hooper J, Oldershaw PJ, Moat NE. Plasma brain natriuretic peptide concentrations in patients with chronic mitral regurgitation. J Heart Valve Dis. 1997;6:608–612
  77. Tharaux PL, Dussaule JC, Hubert-Brierre J, et al. Plasma atrial and brain natriuretic peptides in mitral stenosis treated by valvulotomy. Clin Sci (Colch). 1994;87:671–677
  78. Gerber IL, Stewart RA, Legget ME, et al. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation. 2003;107:1884–1890
  79. Suda K, Matsumura M, Matsumoto M. Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatr Int. 2003;45:249–254
  80. Ribeiro AL, dos Reis AM, Barros MV, et al. Brain natriuretic peptide and left ventricular dysfunction in Chagas' disease. Lancet. 2002;360:461–462
  81. Kawamura T, Wago M. Brain natriuretic peptide can be a useful biochemical marker for myocarditis in patients with Kawasaki disease. Cardiol Young. 2002;12:153–158
  82. Nakao K. Natriuretic peptide family. Nippon Naibunpi Gakkai Zasshi. 1992;68:134–142[in Japanese]
  83. Adachi K, Kawai H, Saito M, et al. Plasma levels of brain natriuretic peptide as an index for evaluation of cardiac function in female gene carriers of Duchenne muscular dystrophy. Intern Med. 1997;36:497–500
  84. Hayakawa H, Komada Y, Hirayama M, Hori H, Ito M, Sakurai M. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol. 2001;37:4–9
  85. Niwa N, Watanabe E, Hamaguchi M, et al. Early and late elevation of plasma atrial and brain natriuretic peptides in patients after bone marrow transplantation. Ann Hematol. 2001;80:460–465
  86. Bordenave L, Georges A, Bareille R, Conrad V, Villars F, Amedee J. Human bone marrow endothelial cells: a new identified source of B-type natriuretic peptide. Peptides. 2002;23:935–940
  87. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004;350:655–663
  88. Nakamura M, Endo H, Nasu M, et al. Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population. Heart. 2002;87:131–135
  89. Bettencourt P, Azevedo A, Pimenta J, Frioes F, Ferreira S, Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004;110:2168–2174
  90. Peacock WF, Freda BJ. Heart failure part I. Emerg Med Rep. 2003;3:89–92
  91. Conklin B. B-type natriuretic peptide: a new measurement to distinguish cardiac from pulmonary causes of acute dyspnea. J Emerg Nurs. 2005;31:73–75
  92. Hartmann F, Packer M, Coats AJ, et al. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation. 2004;110:1780–1786
  93. Gardner RS, Ozalp F, Murday AJ, et al. N-terminal pro-brain natriuretic peptide: a new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J. 2003;24:1735–1743
  94. de Groote P, Dagorn J, Soudan B, et al. B-type natriuretic peptide and peak exercise oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure. J Am Coll Cardiol. 2004;43:1584–1589
  95. Hamada Y, Tanaka N, Murata K, et al. Significance of predischarge BNP on one-year outcome in decompensated heart failure-comparative study with echo-Doppler indexes. J Card Fail. 2005;11:43–49
  96. Miller WL, Hartman KA, Burritt MF, Borgeson DD, Burnett JC, Jaffe AS. Biomarker responses during and after treatment with nesiritide infusion in patients with decompensated chronic heart failure. Clin Chem. 2005;51:569–577
  97. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355:1126–1130
  98. Abdulla J, Kober L, Torp-Pedersen C. Methods of assessing the functional status of patients with left ventricular systolic dysfunction in interventional studies: can brain natriuretic peptide measurement be used as surrogate for the traditional methods?. Cardiovasc Drugs Ther. 2004;18:219–224
  99. Maeder M, Ammann P, Kiowski W, et al. B-type natriuretic peptide in patients with sepsis and preserved left ventricular ejection fraction. Eur J Heart Fail. 2005;7:1164–1167
  100. Chua G, Kang-Hoe L. Marked elevations in N-terminal brain natriuretic peptide levels in septic shock. Crit Care. 2004;8:R248–R250
  101. Tung RH, Garcia C, Morss AM, et al. Utility of B-type natriuretic peptide for the evaluation of intensive care unit shock. Crit Care Med. 2004;32:1643–1647
  102. Forfia PR, Watkins SP, Rame JE, et al. Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit. J Am Coll Cardiol. 2005;45:1667–1671
  103. Charpentier J, Luyt CE, Fulla Y, et al. Brain natriuretic peptide: a marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med. 2004;32:660–665
  104. Ueda S, Nishio K, Akai Y, et al. Prognostic value of increased plasma levels of brain natriuretic peptide in patients with septic shock. Shock. 2006;26:134–139
  105. Cuthbertson BH, Patel RR, Croal BL, et al. B-type natriuretic peptide and the prediction of outcome in patients admitted to intensive care. Anaesthesia. 2005;60:16–21
  106. Henriksen JH, Gotze JP, Fuglsang S, et al. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut. 2003;52:1511–1517
  107. Iwao T, Oho K, Nakano R, et al. High plasma cardiac natriuretic peptides associated with enhanced cyclic guanosine monophosphate production in preascitic cirrhosis. J Hepatol. 2000;32:426–433
  108. Makikallio AM, Makikallio TH, Korpelainen JT, et al. Natriuretic peptides and mortality after stroke. Stroke. 2005;36:1016–1020
  109. Berendes E, Walter M, Cullen P, et al. Secretion of brain natriuretic peptide in patients with aneurysmal subarachnoid haemorrhage. Lancet. 1997;349:245–249
  110. Espiner EA, Leikis R, Ferch RD, et al. The neuro-cardio-endocrine response to acute subarachnoid haemorrhage. Clin Endocrinol. 2002;56:629–635
  111. Fukui S, Katoh H, Tsuzuki N, et al. Focal brain edema and natriuretic peptides in patients with subarachnoid hemorrhage. J Clin Neurosci. 2004;11:507–511
  112. Sviri GE, Feinsod M, Soustiel JF. Brain natriuretic peptide and cerebral vasospasm in subarachnoid hemorrhage (Clinical and TCD correlations). Stroke. 2000;31:118–122
  113. McGirt MJ, Blessing R, Nimjee SM, et al. Correlation of serum brain natriuretic peptide with hyponatremia and delayed ischemic neurological deficits after subarachnoid hemorrhage. Neurosurgery. 2004;54:1369–1373
  114. Liang F, Webb P, Marimuthu A, et al. Triiodothyronine increases brain natriuretic peptide (BNP) gene transcription and amplifies endothelin-dependent BNP gene transcription and hypertrophy in neonatal rat ventricular myocytes. J Biol Chem. 2003;278:15073–15083
  115. Schultz M, Faber J, Kistorp C, et al. Nterminal-pro-B-type natriuretic peptide (NT-pro-BNP) in different thyroid function states. Clin Endocrinol. 2004;60:54–59
  116. Knudsen CW, Vik-Mo H, Omland T. Blood haemoglobin is an independent predictor of B-type natriuretic peptide levels. Clin Sci (Lord) Epub 2005,109:69-74.
  117. Redfield MM, Rodeheffer RJ, Jacobsen SJ, et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002;40:976–982
  118. McCullough PA, Duc P, Omland T, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis. 2003;41:571–579
  119. McLean AS, Huang SJ, Nalos M, Tang B, Stewart DE. The confounding effects of age, gender, serum creatinine, and electrolyte concentrations on plasma B-type natriuretic peptide concentrations in critically ill patients. Crit Care Med. 2003;31:2611–2618
  120. Maffei S, Del Ry S, Prontera C, Clerico A. Increase in circulating levels of cardiac natriuretic peptides after hormone replacement therapy in postmenopausal women. Clin Sci (Colch). 2001;101:447–453
  121. Onuoha GN, Nicholls DP, Patterson A, Beringer T. Neuropeptide secretion in exercise. Neuropeptides. 1998;32:319–325
  122. Ohba H, Takada H, Musha H, et al. Effects of prolonged strenuous exercise on plasma levels of atrial natriuretic peptide and brain natriuretic peptide in healthy men. Am Heart J. 2001;141:751–758
  123. Almeida SS, Azevedo A, Castro A, et al. B-type natriuretic peptide is related to left ventricular mass in hypertensive patients but not in athletes. Cardiology. 2002;98:113–115
  124. Lang CC, Choy AM, Henderson IS, Coutie WJ, Struthers AD. Effect of haemodialysis on plasma levels of brain natriuretic peptide in patients with chronic renal failure. Clin Sci (Colch). 1992;82:127–131
  125. Mueller C, Laule-Kilian K, Scholer A, et al. B-type natriuretic peptide for acute dyspnea in patients with kidney disease. Kidney Int. 2005;67:278–284
  126. McCord J, Mundy BJ, Hudson MP, et al. Relationship between obesity and B-type natriuretic peptide levels. Arch Intern Med. 2004;164:2247–2252
  127. Mehra MR, Uber PA, Park MH, et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol. 2004;43:1590–1595
  128. Silver MA, Maisel A, Yancy CW, et al. BNP consensus panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail. 2004;10:1–30
  129. Tabbibizar R, Maisel A. The impact of B-type natriuretic peptide levels on the diagnosis and management of congestive heart failure. Curr Opin Cardiol. 2002;17:340–345

PII: S0147-9563(07)00109-4

doi: 10.1016/j.hrtlng.2007.05.010

Heart & Lung: The Journal of Acute and Critical Care
Volume 37, Issue 4 , Pages 275-285 , July 2008

Article Tools